Objectives: Though antimicrobial peptides (AMPs) show great potential as novel antibiotics, therapeutic applications are hindered by their low stability, toxicity and high manufacturing cost. Various chemical modification strategies are employed to overcome these problems. However, chemical modifications often significantly increase the manufacturing cost of AMPs with only limited pharmacokinetic advantages. Therefore, we developed AMPs with enhanced stability and cell specificity that can be economically produced.
Introduction
The widespread increase in bacterial resistance to many conventional antibiotics has led numerous researchers to focus on the development of new classes of antibiotics with novel targets and modes of action. One potential source of novel antibiotics is antimicrobial peptides (AMPs), which constitute a major component of the ancient, non-specific innate defence system in most multicellular organisms, forming the first line of defence against invading microbes.
1 -3 Despite the diversity in their structure and amino acid sequences, AMPs can be defined as short (,50 amino acids) peptides possessing an overall positive charge (in general, +2 to +9) and a large percentage (≥30%) of hydrophobic amino acids. 4 These properties permit the peptides to fold into amphipathic conformation upon contact with negatively charged bacterial membranes. Unlike conventional antibiotics, which operate on specific intracellular targets, many AMPs physically and rapidly permeate and destroy the bacterial membrane or essential components inside the cell. Thus, the chances of developing AMP resistance by target modification are slim, as this would require the complete alteration of the membrane and/or bypassing of several biochemical pathways. 5, 6 AMPs are effective at low micromolar concentrations against a broad range of microorganisms, including in many cases those resistant to conventional antibiotics. 7 Because of these properties, AMPs are considered to be potential alternatives to conventional antibiotics and numerous AMPs have been studied in detail to investigate their mechanisms of action and improve their antimicrobial potencies. 8, 9 However, therapeutic applications of these AMPs have been hindered by several problems, such as toxicity, low stability and high cost of production. Many AMPs are toxic to mammalian cells at higher concentrations due to their membrane lytic mechanism. 5 Moreover, AMPs generally have low stability in vivo. For example, though peptides exhibit significant in vitro activity against bacteria, for many AMPs this activity appears to be lost under physiological salt and serum conditions. 10, 11 In addition, these peptides are readily degraded by both endogenous human proteases and proteases secreted by invading microbes, which is likely to be the most important cause of poor in vivo activity. 12, 13 Among the endogenous human proteases, trypsin and chymotrypsin are the greatest threats to AMPs. Trypsin and chymotrypsin attack peptides at basic residues (Lys and Arg) and hydrophobic residues (Trp and Phe), respectively, which are an obligate feature of AMPs. It has also been reported that AMPs are susceptible to degradation by proteases from pathogens. For example, LL-37 is destroyed by Staphylococcus aureus aureolysin, a metalloprotease that belongs to the family of thermolysins. 14, 15 To overcome these problems, researchers have tried to develop novel AMPs with low toxicity and improved stability. It has been reported that toxicity of AMPs can be reduced by modest sequence modifications. 16 -18 Stability problems, however, remain one of the major barriers to the use of AMPs as antibiotics, though several solutions have been proposed. Peptides can be protected from degradation by incorporation of non-natural amino acids (mainly D-form amino acids), modification of the terminal regions (acetylation or amidation) or the use of non-peptidic backbones (peptidomimetics). 19 -21 Unfortunately, these strategies often significantly increase the manufacturing cost of the peptides with only limited pharmacokinetic advantages. The high cost of manufacturing peptides is arguably the principal problem preventing the widespread clinical use of AMPs. 4 Thus, there is a critical need to develop short and compositionally simple peptides with desired activities that can be produced economically. In this study, we tried to develop novel AMPs with enhanced stability and cell specificity consisting entirely of unmodified natural amino acids. We designed several peptides consisting of 15 unmodified natural amino acids while keeping the structural features known to be important for the antimicrobial activity and selectivity of AMPs. In designing the peptides, amino acids were systematically arranged to avoid protease-scissile sites as much as possible. The antimicrobial activities of the designed peptides were tested against both model microorganisms (Gram-positive bacteria, Gram-negative bacteria and fungi) as well as clinically isolated methicillin-resistant S. aureus (MRSA) and vancomycin-resistant enterococci (VRE) under physiologically relevant conditions (e.g. in the presence of serum, salt and proteases). The cytotoxicity of the peptides against human cells such as erythrocytes, skin keratinocytes and fibroblasts was evaluated to verify selective antimicrobial activity. In addition, the b-galactosidase assay and scanning electron microscopy were performed to elucidate the mechanism of action of the peptides. In all studies, magainin 2 and buforin IIb were included as standard AMPs because of their well-established biological activity, structure and mode of action.
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Materials and methods
Microorganisms
The standard test strains used in this study were obtained from the ATCC and the Korean Collection for Type Cultures (KCTC) and included Bacillus 
Peptide preparation
Peptides used in this work (see Table 1 ) were synthesized by the standard Fmoc solid-phase peptide synthesis protocol at Peptron (Daejeon, Korea). Synthesized peptides were purified to .95% by reversed-phase HPLC on a Capcell Pak C18 column (Shiseido, Tokyo, Japan) and their molecular weights were confirmed by liquid chromatography/mass spectrometry (HP 1100 series LC/MSD, Hewlett-Packard, Palo Alto, CA, USA). The peptide content of lyophilized samples was determined by quantitative amino acid analysis with a Pico-tag system on a Beckman 121 MB amino acid analyser (Beckman Coulter, Fullerton, CA, USA).
Antimicrobial activity assay
The antimicrobial activity of the peptides (GNU1-7, magainin 2 and buforin IIb) was determined using the broth microdilution assay as described by Park et al. 25 with a slight modification. Briefly, mid-logarithmic-phase cells were diluted to 5×10 4 cfu/mL in 10 mM sodium phosphate buffer (NAPB), pH 7.4. Each well of 96-well propylene microtitre plates (Costar, Cambridge, MA, USA) was filled with 90 mL of the diluted cell suspension and 10 mL of serially diluted peptide samples (final concentrations ranging from 0.5 to 64 mg/L) and incubated at 378C (bacteria) or 308C (fungi) for 3 h to minimize interference with the peptide's biological activity. Then, fresh medium [trypticase soy broth (TSB) for bacteria and Sabouraud medium for fungi] was added to the mixture and incubated for an additional 16 h at 378C (bacteria) or 308C (fungi). Controls were done without peptides. The inhibition of growth was determined by measuring absorbance at 595 nm with a Model 680 Microplate Reader (Bio-Rad, Hercules, CA, USA). The lowest concentration of peptide that completely inhibited growth was defined as the MIC. The MIC was calculated as the average of three independent experiments performed in triplicate. Where required, NaCl or serum was added to each well of the 96-well plate to obtain the desired physiological condition [150 mM NaCl and 10% serum (v/v), respectively]. 26 
Resistance to proteolytic digestion
Protease resistance of the peptides (GNU5-7, magainin 2 and buforin IIb) was assessed by SDS-PAGE analysis and a growth inhibition assay. To test whether the peptides were digested by proteases, 2 mg of each peptide was incubated with trypsin (Sigma, St Louis, MO, USA), chymotrypsin (Sigma) or aureolysin (BioCol, Potsdam, Germany) at a molar ratio of 5000: 1, 2500 :1 and 50000: 1 (peptide:enzyme), respectively, in the digestion buffer (50 mM Tris -HCl, pH 7.4, 5 mM CaCl 2 ) at 378C. At designated timepoints, the digestion mixture was sampled and analysed by 16.5% tricine-SDS-PAGE. To determine the effect of protease digestion on the antimicrobial activity of the peptide, each peptide was first incubated with trypsin (5000:1), chymotrypsin (2500: 1) or aureolysin (50000: 1) at 378C for 4 h. After heat treatment at 808C for 10 min to halt the enzyme reaction, 10 mLof the sample was added to 90 mL of the diluted S. aureus ATCC 15752 cell suspension (5×10 4 cfu/mL) at a final concentration of 4×MIC of each peptide (irrespective of whether or not it was degraded) and the mixture was incubated at 378C for 3 h. Then, fresh TSB was added to the mixture, which was incubated for an additional 16 h. A sample containing the heat-inactivated protease without the peptide and a bufferonly sample were included as controls. Bacterial growth inhibition was Kim et al.
determined by measuring absorbance at 595 nm with a Model 680 Microplate Reader (Bio-Rad). The experiments were performed in triplicate and done at least three times on different days.
Haemolysis assay
Haemolytic activity was assayed as described by Jang et al. 27 Briefly, 3 mL of freshly prepared human red blood cells (RBCs) was washed with isotonic PBS, pH 7.4, until the colour of the supernatant turned clear. The washed RBCs were then diluted to a final volume of 20 mL with the same buffer. Ten microlitres of peptide samples, serially diluted in PBS (final concentrations ranging from 0.5 to 128 mg/L), was added to 190 mL of the cell suspension in microfuge tubes. Following gentle mixing, the tubes were incubated at 378C for 30 min and then centrifuged at 4000 g for 5 min. Aliquots of 100 mL of supernatant were diluted to 1 mL with PBS and absorbance at 567 nm was measured to monitor the release of haemoglobin, which indicated RBC membrane damage. Zero haemolysis and 100% haemolysis were determined in PBS and 0.2% Triton X-100, respectively. The percentage of haemolysis was calculated using the following equation: haemolysis (%) ¼(A s -A 0 ) /(A 100 -A 0 )×100, where A s is the absorbance of the sample, A 100 is the absorbance of completely lysed RBCs in 0.2% Triton X-100 and A 0 is the absorbance in the complete absence of haemolysis.
Cell culture and in vitro cytotoxicity assay
HaCaT keratinocytes 28 and BJ skin fibroblasts (ATCC number CRL-2522) were cultured in a complete medium (DMEM supplemented with 10% FBS and 0.1% penicillin-streptomycin) in a humidified atmosphere of 5% CO 2 at 378C. Trypsin-EDTA (0.05%) was used to detach cells in subcultures. All cell culture media and reagents were purchased from Lonza (Basel, Switzerland). Cells were seeded onto 96-well plates at a density of 8000 cells/well (HaCaT keratinocytes) or 10000 cells/well (BJ skin fibroblasts) in 0.1 mL of complete medium. After 16 h of incubation, cells were treated with serially diluted peptide samples (final concentrations ranging from 0.5 to 64 mg/L) and incubated for another 24 h. Cell viability was measured with the MTT assay using the CellTiter 96-cell proliferation assay kit (Promega, Madison, WI, USA). The percentage of cell viability was determined using the following equation: viability (%) ¼(A s -A 0 ) / (A c -A 0 )×100, where A s is the absorbance of the sample, A c is the absorbance of the control (no peptide added) and A 0 is the background absorbance. Each experiment was performed in triplicate and done at least three times independently.
Circular dichroism (CD)
The secondary structures of GNU5, GNU6 and GNU7 were analysed using a CD spectrophotometer (J-720, Jasco, Tokyo, Japan). Magainin 2, which has a typical a-helical structure, 22 was included as a standard AMP. Each spectrum (190 -250 nm) was an average of five scans using a quartz cell with a 1 mm path length at room temperature. The scanning speed was 100 nm/ min at a step size of 0.1 nm, a 2 s response time and 1.0 nm bandwidth. Spectra were measured in 10 mM NAPB (mimicking an aqueous environment) and 10 mM NAPB containing 20 mM SDS (mimicking a membrane environment). A blank spectrum of a sample containing all components except the peptide was subtracted from individual spectra to account for the baseline. The acquired spectra were then converted into mean residue ellipticity using the following equation: mean residue ellipticity [u] MR ¼(u obs ×M RW )/(c×l), where u obs is the observed ellipticity corrected for the buffer at given wavelength (mdeg), M RW is residue mol. wt (mol. wt/number of backbone amides), c is peptide concentration (mg/mL) and l is path length (mm). The secondary structures of the peptides were estimated according to Greenfield and Fasman. 29 
Membrane permeabilization assay
The membrane permeabilization activity of each peptide was determined by measurement of b-galactosidase activity in E. coli ML35 (ATCC 43827), a lactose permease-deficient strain with constitutive cytoplasmic b-galactosidase activity. 30 Mid-logarithmic-phase E. coli cells were resuspended in 10 mM NAPB containing 1% TSB (v/v), and 15 mL of cell suspension (1×10 7 cfu/mL) was added to 135 mL of the same buffer supplemented with 1.5 mM o-nitrophenyl-b-D-galactopyranoside (ONPG), a non-membrane-permeative chromogenic substrate, and each peptide (at a final concentration of 1×MIC). The rate of permeability was evaluated by ONPG hydrolysis to o-nitrophenol over time (up to 120 min) by measuring absorbance at 415 nm on a microplate reader (Bio-Rad).
Field emission scanning electron microscopy (FE-SEM)
Aliquots of 270 mL of cell suspensions containing mid-logarithmic-phase E. coli ML35 (6×10 7 cfu/mL), S. aureus ATCC 15752 (2×10 8 cfu/mL) or C. neoformans ATCC 34881 (2×10 7 cfu/mL) were mixed with 30 mL of peptide samples (at a final concentration of 2×MIC). Controls were run without peptides. After incubation at 378C for 1 h, the cells were pelleted by centrifugation at 3000 rpm for 10 min, followed by washing twice with 0.1 M NAPB. The cells were then fixed at room temperature for 2 h in 2.5% glutaraldehyde, post-fixed in 1% osmium tetroxide at 48C for 2 h and dehydrated using graded ethanol solutions. Upon dehydration, the cells were air dried after immersion in hexamethyldisilazane (Sigma) for 20 min, sputter coated with gold and imaged with a Philips XL30S FEG (Amsterdam, the Netherlands).
Results
Peptide design
To develop peptides with high efficacy, selectivity and stability, we designed and synthesized seven new AMPs consisting of 15 unmodified natural amino acids (Table 1) based on the following criteria: (i) all of the peptides were designed to be amphipathic when folded into a-helical structures, by converging the hydrophobic residues into one side and the polar residues into the other side of the helical axis ( Figure 1 ); (ii) the structural features that are known to be crucial for effective antimicrobial activity and selectivity of AMPs were maintained; and (iii) amino acids were arranged to avoid protease-scissile sites as much as possible. Previous studies on the structure-activity relationship of a-helical peptides revealed that hydrophobic and polar face depths are important in modulating membrane interaction and antimicrobial activity. 31 Thus, amino acids with long aliphatic side chains, such as Val, Leu, Ile and Gln, were used in designing the peptides to increase both the hydrophobic and polar face depths. Overall hydrophobicity is known to be important for the antimicrobial activity of AMPs, but AMPs with toxic effects on mammalian cells possess the highest hydrophobic content among the natural AMPs in the Antimicrobial Peptide Database (APD, http://aps.unmc.edu/AP). Hawrani et al. 17 reported that disruption of the hydrophobic face of the a-helical peptides reduces mammalian cell toxicity because of a greatly reduced affinity for neutral membranes. Therefore, we adjusted the hydrophobic content of the peptides to ,50% (Table 1) and disrupted the hydrophobic face by inserting a single Lys residue (K 13 ) (Figure 1 ). To improve peptide stability to proteases, the length of the peptides was kept short (15 amino acids) and the amino acids were arranged to avoid protease-scissile sites as much as possible. For example, to protect the peptides from degradation by trypsin, Novel antimicrobial peptides with enhanced stability and cell specificity Pro (P 5 ) was placed at the carboxyl side of Arg (R 4 ) and Glu (E 12 ) was placed between the two Lys residues (K 11 and K
13
). The rate of hydrolysis by trypsin is slower if an acidic residue is on either side of the cleavage site and no cleavage occurs if a Pro residue is on the carboxyl side of the cleavage site. 32 In order to impede tryptic digestion, we also used Lys instead of Arg at the scissile site because trypsin has up to 10-fold greater affinity for Arg than for Lys. 33 In addition, Trp and Phe were not used in the hydrophobic face of the peptides because chymotrypsin preferentially cleaves at Trp and Phe in P1 position. 34 Chymotrypsin also catalyses the hydrolysis of the peptide bond on the carboxyl side of Leu. Because the cleavage activity of chymotrypsin is enhanced when hydrophobic and positively charged residues are placed in the P2 and P1
′ positions, respectively, 35 we avoided these residues in the P2 and P1 ′ positions when Leu was used in the peptide sequence.
Under these rules, we initially designed GNU1, which contained 33% of hydrophobic residues (five Val residues). Starting from GNU1, we replaced one or two Gly residues (G 2 and G 9 ) in the polar face with Val to increase the hydrophobicity of the non-polar face, thereby obtaining GNU2 and GNU4 (40% and 46% of hydrophobic residues, respectively). Then, to evaluate the impact of acidic residues in the polar face, we replaced Glu (E 12 ) in GNU2 and GNU4 with Gln, thus obtaining GNU3 and GNU5. The hydrophobicity of peptides was further increased by replacing all the Val residues in GNU5 with Ile (GNU6) or Leu residues (GNU7).
Antimicrobial activity of the designed peptides
A first round of antimicrobial assays was performed on standard laboratory microbial strains under standard antimicrobial activity Figure 1 . Helical wheel projections of the designed peptides. Grey and white circles represent hydrophobic and hydrophilic residues, respectively. Kim et al.
assay conditions (Table 2 ). Among the designed peptides, GNU5 displayed antimicrobial activity similar to that of magainin 2. GNU6 and GNU7 showed stronger antimicrobial activity than GNU5. For all species tested, the MIC values of GNU6 and GNU7 ranged from 2 to 4 mg/L, which are comparable to those of buforin IIb and 4 -8 times lower than those of magainin 2 (MICs 2 -32 mg/L). We then tested the antimicrobial activity of GNU5, GNU6 and GNU7 against standard laboratory microbial strains under physiologically relevant conditions. In the presence of 150 mM NaCl, GNU5 completely lost antimicrobial activity (Table 3) . GNU6 and GNU7, however, maintained their activity in this high-salt condition. MIC values of GNU6 against bacteria and fungi were in the range of 8-32 mg/L in the presence of 150 mM NaCl. In particular, the antimicrobial activity of GNU7 in the high-salt condition (MICs 4 -8 mg/L) was found to be only slightly lower than that of buforin IIb (MICs 2-4 mg/L), a well-known saltresistant AMP. 23, 24 In the presence of 10% serum, all of the peptides showed some decrease in antimicrobial activity (Table 4) . Once again, GNU6 and GNU7 maintained antimicrobial activity in the presence of 10% serum, although there was a small increase in MICs (4 -32 mg/L). Next, we extended the antimicrobial assay of GNU5, GNU6 and GNU7 to a panel of clinically isolated antibiotic-resistant bacteria, covering five MRSA strains and five VRE strains (Table 5 ). GNU5 was found to be mainly active Average of three independent experiments performed in triplicate. Novel antimicrobial peptides with enhanced stability and cell specificity against VRE strains, whereas GNU6 and GNU7 manifested potent antimicrobial activity against all tested antibiotic-resistant bacteria (MICs 2 -4 mg/L and 1-2 mg/L, respectively). Overall, GNU5, GNU6 and GNU7 demonstrated potent antimicrobial activity and broad antimicrobial spectra. In addition, GNU6 and GNU7 maintained antimicrobial activity under physiologically relevant conditions and showed potent antimicrobial activity against clinically isolated MRSA and VRE strains.
Protease resistance of the designed peptides
One of the major limitations of AMPs for clinical use is inactivation by both endogenous human proteases and proteases secreted from invading microbes. To test the protease resistance of GNU5, GNU6 and GNU7, they were incubated with various proteases for up to 12 h and the digestion mixtures were analysed by tricine-SDS-PAGE. As shown in Figure 2 (a), GNU5 and GNU6 were not digested at all by proteases such as trypsin, chymotrypsin and aureolysin when exposed to them for up to 12 h. GNU7 was completely resistant to digestion by trypsin and aureolysin, but a small amount of GNU7 was cleaved by 4 h of incubation with chymotrypsin. However, a band corresponding to GNU7 was still present even after 12 h of incubation, indicating that chymotrypsin worked incompletely as a protease. We also conducted the same experiment with magainin 2 and buforin IIb as controls. In contrast to GNU5, GNU6 and GNU7, magainin 2 was cleaved by proteases as early as Kim et al.
h and completely disappeared from the gel after 4 h (trypsin and chymotrypsin) or 8 h (aureolysin)
. Buforin IIb was even more rapidly degraded by proteases than magainin 2; it was cleaved to small fragments by trypsin, chymotrypsin and aureolysin as early as 1 min. We then determined the effect of protease digestion on the antimicrobial activity of GNU5, GNU6 and GNU7. Each peptide was incubated with trypsin, chymotrypsin or aureolysin for 4 h and antimicrobial activity against S. aureus ATCC 15752 was assessed by the growth inhibition assay. As shown in Figure 2(b) , GNU5, GNU6 and GNU7 maintained their potent antimicrobial activity after 4 h of incubation with each protease. In contrast, the antimicrobial activities of magainin 2 and buforin IIb were completely abolished or severely impaired after 4 h of incubation with each protease. When added alone without peptides, the proteases did not affect the growth of S. aureus (data not shown). These results showed that the antimicrobial activity of GNU5, GNU6 and GNU7 was resistant to both endogenous human proteases (trypsin and chymotrypsin) and a protease secreted from invading microbes (aureolysin).
Cytotoxicity of the designed peptides against human cells
For a peptide to be of pharmaceutical interest, high antimicrobial activities must be combined with low toxicity against normal host cells. Therefore, we assessed the cytotoxicity of GNU5, GNU6 and GNU7 by a haemolysis assay (Figure 3a) and an MTT assay using HaCaT keratinocytes and BJ skin fibroblasts (Figure 3b ). The cytotoxicities of GNU5, GNU6 and GNU7 were compared with that of magainin 2, which has no cytotoxicity to human cells, 36 and buforin IIb, which is toxic to human cells. 27 The results showed that buforin IIb, in accordance with previous results, 27 had significant toxic effects at high concentrations. Buforin IIb lysed 14.5% of RBCs at 128 mg/L (Figure 3a) and killed 63.9% of HaCaT keratinocytes and 31.8% of BJ skin fibroblasts at 64 mg/L (Figure 3b ). On the other hand, GNU5, GNU6 and GNU7, like 
Mechanism of action of the designed peptides
Many of the a-helical AMPs permeabilize the lipid bilayer of the cytoplasmic membrane, which results in the dissipation of transmembrane potential and subsequent cell death. 22, 37 To explore the conformational behaviour of GNU5, GNU6 and GNU7, we performed a CD study of these peptides in 10 mM NAPB (mimicking an aqueous environment) and 10 mM NAPB containing 20 mM SDS (mimicking a membrane environment). The spectra of the designed peptides were compared with that of magainin 2, a typical a-helical AMP with membrane-lytic activity. 22 The CD analysis showed that none of the peptides had a defined secondary structure when in aqueous buffer alone (data not shown). However, like magainin 2, GNU5, GNU6 and GNU7 showed a typical a-helical spectrum with two minimum peaks at 208 and 222 nm in 20 mM SDS solution, suggesting that they might exert antimicrobial activity by permeabilization of the cytoplasmic membrane (Figure 4 ). To confirm this possibility, the mechanism of action of GNU6 and GNU7 was investigated using E. coli ML35 as a model microorganism. First, the degree of cytoplasmic membrane permeabilization was analysed by the b-galactosidase assay ( Figure 5 ). E. coli ML35 cells were incubated with the peptides (at a final concentration of 1×MIC) and 1.5 mM ONPG at 378C for up to 2 h. The hydrolysis of ONPG, a chromogenic substrate, by cytoplasmic b-galactosidase was followed spectrophotometrically at 415 nm. Like magainin 2, a wellknown membrane-permeabilizing peptide, 21 both GNU6 and GNU7 showed strong cytoplasmic membrane-permeabilizing activity. We also examined the damage to the E. coli membrane induced by the peptide treatment, using FE-SEM. Figure 6 shows that the integrity of E. coli ML35 membrane upon treatment with GNU6 and GNU7, like magainin 2 treatment, was grossly affected. Similar results were observed for Gram-positive bacteria (S. aureus) and fungi (C. neoformans). S. aureus cells treated with the peptides became roughened. In addition, membrane disruption was observed in numerous bacteria. In the case of C. neoformans, large dents were observed in the cells following incubation with the peptides. Comparison with the untreated control group clearly showed that the peptides caused damage to the membranes of all tested microorganisms, Kim et al.
thereby providing morphological evidence of the potent permeabilizing activities of GNU6 and GNU7.
Discussion
Although AMPs are regarded as promising lead structures in the development of novel broad-spectrum antibiotics, they present several drawbacks that strongly limit their development into therapeutically valuable antibiotics. These include toxicity to eukaryotic cells, low stability in vivo and high cost of production. In order to overcome those obstacles, many methods have been proposed. For instance, it has been reported that replacing Trp and Phe residues with less hydrophobic amino acids 16 or interrupting the hydrophobic patches with basic amino acids 17, 18 decreases the toxicity of AMPs. Introduction of non-natural amino acids (mainly D-form amino acids), 19, 38 modification of the terminal regions (acetylation or amidation), 20 cyclization of linear peptides 39, 40 or the use of non-peptide backbones (peptidomimetics) 21, 41 improved the stability of peptides by preserving them from proteolytic degradation. However, much remains to be elucidated with regard to the pharmacokinetics, antimicrobial activity and toxicity of AMP derivatives designed by the use of non-natural amino acids or peptidomimetics. Therefore, controversy continues to rage over whether these modifications could improve the drug potential of certain AMPs. 42 Moreover, chemical modifications often significantly increase the manufacturing cost of the peptides, which is Novel antimicrobial peptides with enhanced stability and cell specificity 129 JAC another impediment in the development of AMPs for therapeutic use. 4 Because AMPs have relatively high molecular sizes compared with conventional antibiotics, they must be produced using recombinant techniques in order to keep the cost of production low. Numerous biological expression systems have been introduced for the cost-effective production of AMPs. 43 Because of their natural destructive behaviour towards microorganisms, AMPs are often produced by fusing the peptides to a fusion partner protein in the heterologous host; this approach neutralizes the innate bacterial toxicity of AMPs and increases their expression levels. After purification, the recombinant fusion proteins are cleaved to release the AMPs. The use of non-natural amino acids, a modified peptide backbone or chemical modification can enhance peptide stability, but these modified peptides can only be produced by costly chemical synthesis. The cost of chemical synthesis of peptides typically runs in the range of US $100-600/g, which is extremely prohibitive to their mass production for use as therapeutics. 44 The most promising solution to the high production cost would be to develop short and compositionally simple peptides with desired activity that can be produced using biological expression systems. 45 In this study, therefore, we developed novel AMPs with enhanced stability and microbial cell specificity, which consisted entirely of unmodified natural amino acids. The antimicrobial assays demonstrated that, among the seven designed peptides, GNU5, GNU6 and GNU7 possessed remarkable antimicrobial activity and broad antimicrobial spectra when compared with other well-known AMPs such as magainin 2 and buforin IIb (Table 2 ). In particular, GNU6 and GNU7, which had the highest hydrophobicity, showed the strongest antimicrobial activity against both standard laboratory microbial strains and clinically isolated antibiotic-resistant bacteria (Table 5) . These results are consistent with the previous studies showing that overall hydrophobicity is important for the antimicrobial activity of AMPs. 46 -48 Hydrophobicity is an essential feature for AMP-membrane interactions, as it governs the extent to which a peptide can partition into the lipid bilayer. Although hydrophobicity is required for effective membrane permeabilization, increasing levels of hydrophobicity are strongly correlated with mammalian cell toxicity and loss of antimicrobial specificity. 49 Though buforin IIb displayed strong antimicrobial activity, it also affected the viability of human cells at higherconcentrations. On the other hand, GNU6 and GNU7, in spite of having high hydrophobicity, were completely inactive against human RBCs, HaCaT keratinocytes and BJ skin fibroblasts (Figure 3 ). This result is most likely due to the fact that the hydrophobic face of GNU6 and GNU7 was disrupted by inserting a single Lys residue (K 13 ) ( Figure 1 ). As observed in previous studies, disruption of the hydrophobic face of the a-helical peptides reduced mammalian cell toxicity by preventing deeper penetration of the peptide into the hydrophobic core of the neutral membrane. 17, 49 In addition to the overall hydrophobicity, the presence of an acid residue (Glu) in the polar face had a profound effect on the antimicrobial activity of the peptides. GNU4 and GNU5 had identical polar and hydrophobic faces except that Gln (Q 12 ) in GNU5 was replaced with Glu (E 12 ) in GNU4, but the antimicrobial activity of GNU4 was dramatically reduced compared with GNU5. The reduced activityof GNU4 may derive from the decreased electrostatic interaction between the peptide and the negatively charged bacterial surface caused by the Glu residue in the polar face.
Though peptides exhibit significant in vitro activity against bacteria, for many AMPs this activity appears to be lost under physiological salt and serum conditions. 10, 11 Therefore, for potential clinical application, AMPs must retain the ability to kill microbes directly under such physiological conditions. As shown in Tables 3  and 4 , GNU6 and GNU7 maintained their activity in the presence of 150 mM NaCl and 10% serum, although there were small increases in MICs. In particular, GNU7 exhibited much higher salt resistance than GNU5 and GNU6. The antimicrobial activity of GNU7 in the high-salt condition (MICs 4-8 mg/L) was only slightly lower than that of buforin IIb (MICs 2-4 mg/L), a well-known saltresistant AMP. 23, 24 The increase in salt resistance in GNU7 compared with GNU5 and GNU6 could be explained by the fact that the hydrophobic residues used in the sequence of GNU7 (seven Leu residues) have higher membrane binding affinity than those of GNU5 (seven Val residues) and GNU6 (seven Ile residues). Among the three amino acids, Leu has the highest affinity for the lipid bilayer: whole-residue free energies of transfer DG from water to membrane interface (DG wif ) for Val, Ile and Leu are 0.07+0.05, 20.31+0.06 and 20.56+0.04 kcal/mol, respectively. 50 Therefore, Leu residues are more likely to enhance the affinity of the peptide for the bacterial membrane, hence compensating the competition from the cations to the negatively charged bacterial cell surface.
One of the main issues associated with the use of therapeutic peptides such as AMPs is inactivation by both endogenous human proteases and proteases secreted from invading microbes. 12, 13 Poor protease stabilityseverely limits the clinical use of AMPs. The protease resistance assay demonstrated that GNU5, GNU6 and GNU7 were not digested by endogenous human proteases such as trypsin and chymotrypsin on incubation for up to 12 h and maintained their potent antimicrobial activity even after 4 h of incubation with each protease (Figure 2 ). GNU7, unlike GNU5 and GNU6, has seven Leu residues that are potentially vulnerable to chymotryptic digestion. However, only a small amount of GNU7 was cleaved after 4 h of incubation and a band corresponding to GNU7 was still visible even after 12 h of incubation, thereby indicating that chymotrypsin worked incompletely as a protease. This could be explained by the fact that chymotrypsin requires a hydrophobic residue in the P2 position and a positively charged residue in the P1 ′ position for optimal cleavage activity. 35 We did not use these residues in the P2 and P1
′ positions of GNU7. The designed peptides GNU5, GNU6 and GNU7 were also resistant to degradation by aureolysin, which was previously shown to have a role in staphylococcal immune escape as it cleaves the cathelicidin-derived peptide LL-37.
14 Many significant human pathogens inactivate effector molecules of innate immunity, such as lysozyme and AMPs, through proteolysis. 51, 52 Thus, from a therapeutic point of view, resistance of GNU5, GNU6 and GNU7 to bacterially induced proteolysis could augment their therapeutic value against pathogens that are able to secrete proteases. Though magainin 2 and buforin IIb displayed low MICs for S. aureus (Tables 2-4), they were rapidly degraded upon incubation with aureolysin and their antimicrobial activity was abolished after 4 h of incubation with aureolysin ( Figure 2 ). This discrepancy could be explained by the fact that most wild-type S. aureus strains, except the sarA mutant, which is deficient in expression of the negative regulator of aureolysin, produce very weak aureolysin activity only in the post-exponential growth phase. 14, 53 Considering that we used mid-logarithmic-phase S. aureus cells that were washed and diluted in NAPB, only a very small amount of aureolysin might be secreted by S. aureus in the assay buffer and thus the peptides could be inactivated only by incubation with exogenously added aureolysin.
Based on the fact that GNU6 and GNU7 maintained antimicrobial activity under physiologically relevant conditions (e.g. in the presence of serum, salt and proteases) and showed potent antimicrobial activity against clinically isolated MRSA and VRE strains without causing human cell cytotoxicity, these peptides appear to be promising candidates for future development as novel antimicrobial agents. Hence, these peptides were further studied for their ability to kill microbial cells using E. coli ML35 as a model microorganism. Many of the a-helical AMPs, such as magainin 2, have been reported to act on the bacterial membrane by forming pores and eventually destroying the integrity of the bacterial membrane. 22, 37 The fact that GNU6 and GNU7 retained a typical a-helical structure in the membrane-mimicking environment suggested that these peptides exert antimicrobial activity via the permeabilization of the bacterial membrane (Figure 4 ). To test this hypothesis, the b-galactosidase assay was performed. As expected, treatment of E. coli ML35 with each peptide caused a graded release of cytoplasmic b-galactosidase ( Figure 5 ). In FE-SEM studies performed with E. coli, S. aureus and C. neoformans, we observed that the peptides caused damage to the membranes of all tested microorganisms, thereby providing morphological evidence of the potent permeabilizing activity of GNU6 and GNU7 ( Figure 6 ). Taken together, these results indicated that membrane disruption might be the primary mode of action of GNU6 and GNU7, though the involvement of other mechanisms cannot be ruled out.
In conclusion, we successfully designed novel AMPs with enhanced stability and cell specificity by systematic amino acid arrangement without incorporating non-natural amino acids or peptidomimetics. GNU6 and GNU7 showed potent antimicrobial activity against bacteria and fungi and maintained their activity in the presence of 150 mM NaCl and 10% serum. In addition, these peptides were not digested by proteases such as trypsin, chymotrypsin and aureolysin when exposed to them for up to 12 h and showed potent antimicrobial activity against clinically isolated MRSA and VRE strains without causing human cell cytotoxicity. Importantly, because GNU6 and GNU7 did not contain either non-natural or chemically modified amino acids, they can be produced in a cost-effective manner in biological expression systems. These features of GNU6 and GNU7 suggest that they might overcome serious problems that currently prevent the clinical use of AMPs (low stability in vivo, toxicity to mammalian cells and high cost of production) and be developed as novel antimicrobial agents.
